Inflammatory Myofibroblastic Tumor Showing Durable Remission after Anthracycline-Containing Cytotoxic Chemotherapy: Report of a Case / 대한내과학회지
Korean Journal of Medicine
;
: 749-753, 2012.
Article
in Korean
| WPRIM
| ID: wpr-741103
ABSTRACT
An inflammatory myofibroblastic tumor (IMT) is a rare disease entity, and the clinical characteristics range from indolent to aggressive forms. No established management for patients with unresectable or aggressive IMT is available. We report on a 62-year-old patient with aggressive IMT who achieved a durable partial response lasting 12 months after anthracycline-containing cytotoxic chemotherapy without corticosteroids. The patient was admitted for an evaluation of progressive weight loss and lower abdominal pain lasting for 2 weeks. Abdominopelvic computed tomography revealed a 10 cm sized heterogeneous mass in the mesentery that encased the superior mesenteric artery and a liver metastasis. The diagnosis of IMT was confirmed by percutaneous core needle biopsy of the mesenteric mass. Systemic chemotherapy was performed after confirming disease progression during a 1 month observation period. A partial response was obtained after two cycles of chemotherapy. Anthracycline-containing cytotoxic chemotherapy could be a treatment option for patients with aggressive IMT.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Piperidones
/
Weight Loss
/
Abdominal Pain
/
Mesenteric Artery, Superior
/
Adrenal Cortex Hormones
/
Disease Progression
/
Rare Diseases
/
Benzeneacetamides
/
Myofibroblasts
/
Biopsy, Large-Core Needle
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS